Clinical trial
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat…
NCT00130286 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00130286 |
|---|---|
| Title | Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance |
| Official title | Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes |
| Intervention type | Drug |
| Interventions | Rosiglitazone, Recombinant human growth hormone + rosiglitazone |
| Enrollment | 77 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Aug 15, 2005 |
| Last update posted | Feb 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: